A Study of the Safety, Dosing, and Delivery of NEO100 in Patients With Pediatric Brain Tumors
← catalyst calendarNCT06357377 · readout ≤ 73 d
Sponsored by Neonc Technologies, Inc. (industry) · NTHI — their whole pipeline →.
Phase
Phase 1
Status
Not yet recruiting
Study type
Interventional
Design
Na · None · Treatment
Enrollment
12estimated
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | Jan 2026 | estimated | When the study began enrolling |
| Primary completion | Oct 2026 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Oct 2026 | estimated | The whole study's end, after follow-up |
| First posted | 2024-04-10 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-01-14 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Pediatric Tumor of CNS
- Pediatric Tumor of Brain
- Diffuse Midline Glioma, H3 K27M-Mutant
- Pediatric Tumor of Brain Stem
- Pineocytoma
- Choroid Plexus Carcinoma, Childhood
- Spinal Cord Tumor
- High Grade Glioma
Intervention
- Drug: NEO100
Primary outcome
what the primary-completion date above is the date OFNature and severity of adverse events
measured 6 months
Permalink · NTHI's whole pipeline · Catalyst calendar · Every registered study · What changed